Peptides 101: a women's guide to reading the research

Read enough peptide research and a pattern surfaces that is hard to unsee: the subjects are almost always male. Male rats, male mice, male cell lines, and, when a compound finally reaches people, study populations that still skew male. If you are a woman trying to understand what a peptide might do in your body, that pattern is the whole problem, and it is the reason this site exists. This guide is the starting point: what these compounds are, how we grade the evidence, and why the question of who was in the studies sits at the center of everything.

What a research peptide actually is

A peptide is a short chain of amino acids, the same building blocks that make up proteins, just fewer of them linked together. BPC-157, for example, is a pentadecapeptide, which simply means a 15-amino-acid chain. Because these are small, defined molecules, they are useful as research materials: investigators can study how one specific sequence interacts with one receptor or pathway without the complexity of a full protein. The phrase research peptide is doing important work here. Most of the compounds discussed in this space are supplied for in-vitro and laboratory research only, not for human use, and most have never been tested in controlled human trials; their evidence is preclinical, meaning it comes from cell cultures and animal models. A few, like semaglutide and bremelanotide, have crossed into approved medicine, and keeping those two categories separate is the first skill in reading this literature honestly.

How the evidence grade works on this site

Every compound here carries an evidence grade from A to E, and the important thing about that grade is that it is derived, not hand-assigned. It is calculated from the underlying study record: how many studies exist, what stage they reached, whether they were in animals or humans. We show you the derivation rather than just the letter, so the grade doubles as a receipt, and a compound with a large approved-drug trial program lands very differently from one resting on a handful of rodent papers. Alongside the grade, each profile tracks a research status, from preclinical, through early human, to approved. Semaglutide, an approved GLP-1 receptor agonist studied across large programs, sits at one end; a compound with animal-only data sits at the other. The status tells you how far a compound has traveled toward people, the grade how much evidence backs it at that stage. You can read the full derivation logic on the methodology page.

• Research status: how far a compound has traveled, from preclinical to early human to approved.
• Evidence grade (A to E): derived from the study record, never assigned by opinion.
• Study counts: total studies, studies that included women, and studies that reported outcomes by sex, each shown as its own number.
• Knowledge state: for every women's-angle field, whether the answer is evidence, no evidence, unstudied, or contraindicated.

The female-evidence lens

Here is what makes this catalog different. For every compound we record not just how many studies exist, but how many included women, and how many reported their results separately by sex. When the answer is none, we say so plainly. Unstudied is treated as a real, first-class state, not a blank we are tempted to fill, because a plausible-sounding guess about how a peptide behaves across the menstrual cycle, or in perimenopause, or alongside a contraceptive, would destroy the only thing this site is for. BPC-157 shows the gap at its widest. The mechanism data on angiogenesis and tissue repair is real, but no controlled human trials have been indexed, the small number of studies using female animals reported no sex-stratified outcomes, and there are no data on cycle, hormonal, or pregnancy interactions. Any dosing figure circulating for it is extrapolated from male-animal data; that is not a knock on the compound, but an honest description of an empty column. Semaglutide sits further along: its large trials enrolled substantial numbers of women, so its female evidence is direct rather than extrapolated. Even so, the record is not complete, because appetite and nausea effects have not been systematically evaluated across menstrual cycle phases, and its outcomes are not stratified by menopausal status. Better evidence is still not finished evidence, and the profile says which parts are which.

Bremelanotide, also known as PT-141, is the exception that proves the rule. It is a melanocortin receptor agonist approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women. That is a rarity in this field: an indication developed and trialed primarily in women, which makes its efficacy evidence female-direct rather than male-extrapolated. It is the compound most others get compared against precisely because the studies behind it were run in women. Even here, though, some questions stay open, such as how as-needed dosing interacts with specific cycle phases, and the profile marks those unstudied.

How to use this site

Put together, a profile here is meant to be read in a specific order: what the compound is, how far its research has traveled, what grade that research earns, and then the female-evidence rows that tell you whether any of it was measured in bodies like yours. When those rows say unstudied, that is the finding, not a gap we are apologizing for. Everything on this site is research and education framing, not a recommendation to use anything. The value is in the honesty of the columns: a compound with real mechanism data and no female evidence, like BPC-157, is described exactly that way, while a female-direct compound like bremelanotide is given its due without overreaching. Start with any profile that interests you and read the female-evidence section first; that is the lens the whole catalog is built around.